Research article · 15 Apr 2026
Conference abstractPublished 29 Sep 2016
Indoxyl sulfate: A new link between chronic kidney disease and coagulation disorders in CKD patients on conservative treatment
Medical University of Bialystok, Poland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: Patients with chronic kidney disease (CKD) are at higher risk of incidence of thromboembolic events. The effect of continuous loss of function of nephrons is a progressive accumulation of uremic toxins. Indoxyl sulfate (IS) is an aggressive uremic toxin exerting proinflammatory and prooxidative properties, which affects multiple signaling pathways. Aim: We examined the association between indoxyl sulfate and activation of the coagulation system in predialysis patients with CKD. Methods: Studies have been conducted on a group of 53 patients with CKD on conservative treatment and 18 healthy volunteers. For the determination of parameters of coagulation ELISA-immuno-enzymatic kits were used, whereas the IS levels were determined by HPLC. The hematological and biochemical parameters were assessed using standard laboratory methods. Results: IS concentration was about three-fold higher in CKD patients compared to controls (p<0,0001). Parameters of coagulation: Von Willebrand factor (vWF), thrombomodulin (TM), tissue factor (TF) and its inhibitor-tissue factor pathway inhibitor (TFPI), prothrombin fragment 1+2 (F1+2) in uremic group were significantly higher than in control group (all p<0,0001). IS levels were positively correlated both with CKD markers and all mentioned above coagulation factors, and these results were also statistically significant (all p<0,0001, râÂ?¥0,45). Moreover, we found inverse correlation between IS and some hematological parameters (HCT, HGB, WBC, LIM and RBC). Conclusions: The results demonstrate a strong relationship between indoxyl sulfate and coagulation parameters in CKD patients. It opens a new idea that IS can play a crucial role in the occurrence of thromboembolic events in CKD patients.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Kaminski T”
- BylineArticles whose byline prints “Karbowska M”
- BylineArticles whose byline prints “Pawlak K”
- BylineArticles whose byline prints “Myśliwiec M”
- BylineArticles whose byline prints “Pawlak D”
